Immuron (NASDAQ:IMRN) Announces Quarterly Earnings Results

Immuron (NASDAQ:IMRN) issued its quarterly earnings results on Thursday. The company reported ($0.10) earnings per share (EPS) for the quarter, FiscalAI reports. The business had revenue of $1.40 million during the quarter.

Immuron Stock Up 1.9%

NASDAQ IMRN traded up $0.02 during trading on Thursday, reaching $0.82. 12,328 shares of the company’s stock were exchanged, compared to its average volume of 38,821. Immuron has a 1 year low of $0.68 and a 1 year high of $2.39. The company has a 50 day moving average price of $0.81 and a two-hundred day moving average price of $1.14.

Hedge Funds Weigh In On Immuron

An institutional investor recently bought a new position in Immuron stock. Citadel Advisors LLC purchased a new position in Immuron (NASDAQ:IMRN) during the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 19,562 shares of the company’s stock, valued at approximately $37,000. Citadel Advisors LLC owned 0.29% of Immuron at the end of the most recent reporting period. Hedge funds and other institutional investors own 0.12% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Immuron in a research report on Friday, March 27th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Immuron has a consensus rating of “Sell”.

About Immuron

Immuron Limited, a biopharmaceutical company, researches and develops oral immunotherapy polyclonal antibodies for the treatment and prevention of infectious and immune modulated diseases in Australia, the United States, and internationally. The company operates through two segments, Research and Development, and Hyperimmune Products. The company markets Travelan and Protectyn for the prevention of travellers' diarrhea. Its lead product candidates include IMM-124E that is in Phase II clinical trials for non-alcoholic steatohepatitis, severe alcoholic hepatitis, and non-alcoholic fatty liver disease, as well as used in antiviral activity against the COVID-19 virus in laboratory studies; and IMM-529, a clinical stage product for clostridium difficile infections.